老虎證券

BRIEF-Unprecedented Results From The Phase 3 MajesTEC-3 Study Support TECVAYLI Plus DARZALEX FASPRO As A Potential Standard Of Care As Early As Second Line For Patients With Relapsed/Refractory Multiple Myeloma

Reuters
2025/12/09
BRIEF-Unprecedented Results From The Phase 3 MajesTEC-3 Study Support TECVAYLI Plus DARZALEX FASPRO As A Potential Standard Of Care As Early As Second Line For Patients With Relapsed/Refractory Multiple Myeloma

Dec 9 (Reuters) - Johnson & Johnson JNJ.N:

  • UNPRECEDENTED RESULTS FROM THE PHASE 3 MAJESTEC-3 STUDY SUPPORT TECVAYLI® PLUS DARZALEX FASPRO® AS A POTENTIAL STANDARD OF CARE AS EARLY AS SECOND LINE FOR PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

  • J&J - TECVAYLI AND DARZALEX SHOW SIGNIFICANT SURVIVAL ADVANTAGE

  • J&J - SUBMITS SBLA FOR TECVAYLI AND DARZALEX COMBINATION AS TREATMENT FOR RRMM

Source text: ID:nPn84198Ca

Further company coverage: JNJ.N

((Reuters.Briefs@thomsonreuters.com;))

應版權方要求，你需要登入查看該內容

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10